Lon S. Schneider

Lon S. Schneider, MD, MS is Professor of Psychiatry & the Behavioral Sciences at the Keck School of Medicine of the University of Southern California, where he holds the Della Martin Chair in Psychiatry and Neuroscience. He directs the USC California Alzheimer's Disease Center (funded by the California Department of Health Services), the Geriatric Studies Center, and co-directs the clinical core of the USC NIA Alzheimer's Disease Research Center.

Dr. Schneider's research focuses on treatment development with novel metabolic and neuroregenerative compounds, outcomes assessment, and approaches to modeling, clinical trials methods and simulations, and in silico screening of medications for slowing Alzheimer's disease. His work spans Alzheimer's disease therapeutics, clinical trial methodology, neuropsychopharmacology, dementia prevention, and neurodegenerative biomarkers. His recent publications demonstrate expertise in amyloid and tau biomarkers, clinical trial design, agitation management in dementia, and cross-cultural studies of cognitive decline.

Dr. Schneider serves as an associate editor or editorial board member for several publications and is a member of The Lancet Commission on dementia prevention, intervention, and care. His research has significantly influenced clinical practice and trial design in Alzheimer's disease.

• Woodward/White, Inc.: The Best Doctors in America, 1992-2009
• Fellow of the American College of Neuropsychopharmacology
• Distinguished Life Fellow of the American Psychiatric Association

Dr. Schneider has mentored numerous researchers and clinicians in the field of geriatric psychiatry and Alzheimer's disease research. His work on the CitAD trial examining citalopram for agitation in Alzheimer's dementia represents one of the largest studies of its kind. He has contributed significantly to understanding the relationship between neuropsychiatric symptoms and functional decline in dementia, as well as developing novel measures for Alzheimer's disease prevention trials.

His laboratory and clinical research programs focus on identifying biomarkers of disease progression, developing novel therapeutic approaches for Alzheimer's disease, and improving clinical trial methodology for neurodegenerative disorders. Dr. Schneider collaborates extensively with researchers across USC and internationally on multi-center clinical trials and observational studies of dementia.